Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
stent implantation · 1 trial · 4 indications
| Name | Type | Description |
|---|---|---|
| stent implantation | DEVICE | - |
Inclusion Criteria: * chronic symptomatic atherosclerotic disease in the iliac arteries (Fontaine Class IIa, IIb, and III) * atherosclerotic de novo or restenotic lesions in the common and/or external iliac artery. * baseline diameter stenosis of \> or = 50% * reference vessel diameter \> or = 5mm ...
Stent implantation is used for arterial occlusive disease, including intermittent claudication, atherosclerotic disease, and thrombosis. It is being studied for treating stenosed or occlusive atherosclerotic disease in the iliac arteries. The procedure involves placing a stent to help keep the artery open and restore blood flow.
stent implantation is developed by Boston Scientific Corporation, a medical device company traded on the New York Stock Exchange under the ticker BSX. The company is conducting clinical research on this device for the treatment of arterial occlusive disease.
stent implantation is in Phase 3 clinical development. It is an investigational device and has not yet been approved by regulatory authorities. The Phase 3 trial has been completed, and the device is being evaluated for safety and efficacy in patients with arterial occlusive disease.
stent implantation is associated with one completed Phase 3 clinical trial, NCT00352222, titled "Safety and Efficacy of Express LD to Treat Stenosed or Occlusive Atherosclerotic Disease in Iliac Arteries." The trial enrolled 150 participants across Belgium, Canada, Czechia, Netherlands, and Poland, and included adults aged 18 years and older.
Yes, stent implantation is the same as Express LD. The clinical trial NCT00352222 evaluates the Express LD stent for treating stenosed or occlusive atherosclerotic disease in the iliac arteries. This device is being developed by Boston Scientific Corporation for patients with arterial occlusive disease.